First Eagle Investment Management LLC Has $7.68 Million Holdings in InfuSystem Holdings, Inc. (NYSE:INFU)

First Eagle Investment Management LLC grew its stake in InfuSystem Holdings, Inc. (NYSE:INFU) by 25.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 908,371 shares of the company’s stock after buying an additional 186,668 shares during the period. First Eagle Investment Management LLC owned approximately 4.27% of InfuSystem worth $7,676,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in INFU. BNP Paribas Financial Markets lifted its position in shares of InfuSystem by 66.4% in the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after buying an additional 1,626 shares during the last quarter. Legato Capital Management LLC acquired a new stake in shares of InfuSystem in the fourth quarter worth about $85,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of InfuSystem in the third quarter worth about $87,000. JPMorgan Chase & Co. lifted its position in shares of InfuSystem by 74.1% in the third quarter. JPMorgan Chase & Co. now owns 15,556 shares of the company’s stock worth $104,000 after buying an additional 6,623 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of InfuSystem by 300.5% during the 3rd quarter. Barclays PLC now owns 28,597 shares of the company’s stock worth $192,000 after purchasing an additional 21,457 shares during the last quarter. Institutional investors and hedge funds own 71.13% of the company’s stock.

InfuSystem Price Performance

NYSE INFU opened at $5.55 on Friday. InfuSystem Holdings, Inc. has a twelve month low of $5.28 and a twelve month high of $9.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. The stock has a market capitalization of $116.60 million, a PE ratio of 92.52 and a beta of 1.75. The stock has a 50-day simple moving average of $7.65 and a 200 day simple moving average of $7.55.

Analysts Set New Price Targets

Separately, StockNews.com raised InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.